Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

iRNAs, as Silence has clearly been shown to be at the forefront of efficient and safe delivery of siRNAs and miRNAs, a process critical to the ultimate success of what promises to be a new and exciting class of targeted cancer therapeutics. Mirna has developed a strong intellectual property position in the therapeutic use of miRNAs in cancer, and has established a broad pipeline of key tumor suppressor miRNAs as potential new targeted therapeutic candidates against both solid and haematological cancers. An efficient delivery technology that provides for systemic delivery of therapeutically effective dose-levels of these miRNAs to their intended targets is a key element in their potential success in the clinic."

Silence's proprietary lipid delivery technology AtuPLEX™ has demonstrated the broad systemic delivery to the vascular endothelium. Formulations generated with the AtuPLEX™ technology can be lyophilized (freeze dried) significantly improving stability, shipping and handling.

Silence is currently conducting a Phase I trial with Atu027 which is based on AtuPLEX™ in patients with advanced solid cancer. Interim data analysis from this trial were presented at the 2011 American Society of Clinical Oncology conference and showed that Atu027 is safe and well tolerated and provided broad support for AtuPLEX™ as an effective siRNA delivery technology with the potential to overcome the recognized delivery challenges currently associated with RNAi therapeutics.

DBTC is the latest delivery system developed by scientists at Silence and allows functional targeted delivery to the liver. Unlike Silence's established delivery technologies, DBTC is a novel lipid-based formulation that functionally delivers to liver endothelial cells, hepatocytes and to other cell types of the liver. As with AtuPLEX™, DBTC can be lyophilized.

Notes for editors                 <
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership with ... Foundation funded a $3.25 million project to relocate and ... most up-to-date features and technology. , The new pharmacy ... staff members will begin moving from the current location ... days. , The current pharmacy has been using ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... The global genotyping market is expected to grow at ... 2015 to 2020 to reach $17.0billion in 2020. Genotyping ... development process and to provide personalized therapy, factors that ... by key manufacturers to offer advanced and innovative products ... 113 market data tables & 37 figures spread through ...
(Date:5/20/2015)...  Cypher Genomics, Inc., a leading genome informatics ... to apply Cypher,s Coral TM technology to ... response to innovative medicines. The information generated from ... access to the right medicine at the right ... and potentially inform new companion diagnostics.  ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... , Milwaukee, Wis. Merge ... leading medical imaging software and services company, today announced ... Advanced Visualization and Clinical Application software modules. This ... software includes customer-driven updates and features that further accelerate ...
... Brookfield, Wis. Fiserv, Inc. announced strong ... share-diluted from continuing operations for the third quarter of 2005 ... the third quarter of 2004. Processing and services revenues were ... of 2004. "We are also very excited about ...
... RedPrairie Corporation , a ... that enables business process transformation, ... of the top 20 retailers ... Performance Management to optimize their ...
Cached Biology Technology:
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... -- Through a well-rounded UAS delegation representing private industry, government, and ... at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people from ... UAS ecosystem. "Our message is clear and ... Rich Knoll . "If you want to fly UAS, ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... in which the circulating strains of influenza showed genetic ... flu shot was found to be effective in preventing ... vaccine also prevented illnesses but was less effective. , ... infection, a University of Michigan study found. , ...
... Muscle weakness and fiber deterioration seen in muscular dystrophy ... under study for their effects against cancer, a Burnham ... on the potential use of these drugs, called histone ... muscles, thereby countering the progression of the disease, in ...
... an innovative new project being developed by Central Queensland ... around the country could soon have access to rehabilitation ... than having to travel to special outpatient clinics. , ... on-line outpatient rehabilitation service for people who have had ...
Cached Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... Digital shaking water bath, with a ... baths and shaking water baths with seamless, ... comfort. The bright MULTI-DISPLAY (LED) indicating up ... across the lab. Advanced MICROPROCESSOR technology with ...
... Features Provides a buffered anti-freeze environment ... , Maintains a liquid, low viscosity solution ... conjugate is necessary and sampling is convenient ... growth during long-term storage Protect enzyme ...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: